Equity Profile

ERAS

Erasca, Inc.

Health CareBiotechnology$3.7B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing treatments for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and attract customers, which is crucial for future success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing treatments for cancer. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as the demand for innovative therapies grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In Q1-2026, Erasca reported an EPS of -$0.60, significantly missing expectations. Despite this, the stock rose by 3.16% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially after the significant EPS miss last quarter. The market is looking for signs of improvement in revenue and cost management.

Bull Case

If Erasca can demonstrate better-than-expected revenue growth and manage R&D expenses effectively, it could signal a turnaround and boost investor confidence.

Bear Case

On the other hand, continued losses and lack of revenue growth could lead to further declines in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Erasca's key drug candidates and their expected timelines?

Investors will be looking for updates on drug development, as successful trials could significantly impact future revenue.

How are R&D expenses being managed in light of the recent EPS miss?

Understanding cost management strategies will be crucial for assessing the company's financial health and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly focused on the recent EPS miss and not considering the potential for significant drug development advancements that could drive future revenue.

Supporting Evidence

Options are pricing a 42.13% move, indicating high expectations for volatility that may not materialize.

The company's historical performance shows a tendency to rebound after misses, suggesting resilience.

Key Risk

If the drug candidates show promising results, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to balance investment in drug development with the need for financial stability.

Bull Confirmed If

A reduction in R&D expenses while achieving revenue growth would confirm the bull case.

Bear Confirmed If

Continued losses and high R&D spending without revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect a volatile reaction post-earnings.

Options price a 42.13% move but the stock has averaged only 5.3% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests the stock could see a modest uptick, confirming a positive trend in drug development.

In-Line / Cautious

If results are in line but cautious, the stock may remain flat as investors await clearer signals of future growth.

Miss

If the company misses expectations again, history suggests a potential drop in stock price, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for key drug candidates.
2Details on cost management strategies for R&D expenses.
3Any partnerships or collaborations that could enhance development efforts.
4Insights into market demand for their therapies.
5Management's outlook on future revenue growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Erasca, Inc. is a biotechnology company focused on developing treatments for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and attract customers, which is crucial for future success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ERAS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-29.90%

Avg Stock Reaction

+1.89%

Last Quarter Recap

In Q1-2026, Erasca reported an EPS of -$0.60, significantly missing expectations. Despite this, the stock rose by 3.16% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially after the significant EPS miss last quarter. The market is looking for signs of improvement in revenue and cost management.

Bull Case

If Erasca can demonstrate better-than-expected revenue growth and manage R&D expenses effectively, it could signal a turnaround and boost investor confidence.

Bear Case

On the other hand, continued losses and lack of revenue growth could lead to further declines in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Erasca's key drug candidates and their expected timelines?

Investors will be looking for updates on drug development, as successful trials could significantly impact future revenue.

How are R&D expenses being managed in light of the recent EPS miss?

Understanding cost management strategies will be crucial for assessing the company's financial health and sustainability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly focused on the recent EPS miss and not considering the potential for significant drug development advancements that could drive future revenue.

Supporting Evidence

Options are pricing a 42.13% move, indicating high expectations for volatility that may not materialize.

The company's historical performance shows a tendency to rebound after misses, suggesting resilience.

Key Risk

If the drug candidates show promising results, it could shift the narrative dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to balance investment in drug development with the need for financial stability.

Bull Confirmed If

A reduction in R&D expenses while achieving revenue growth would confirm the bull case.

Bear Confirmed If

Continued losses and high R&D spending without revenue growth would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±42.13%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect a volatile reaction post-earnings.

Options price a 42.13% move but the stock has averaged only 5.3% over the last 8 quarters — setup is rich.

Detail

ATM IV

0.9%

30d HV

215.7%

Calls (25K)P/C Ratio: 0.16Puts (5K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Erasca beats expectations, history suggests the stock could see a modest uptick, confirming a positive trend in drug development.

In-Line / Cautious

If results are in line but cautious, the stock may remain flat as investors await clearer signals of future growth.

Miss

If the company misses expectations again, history suggests a potential drop in stock price, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timelines for key drug candidates.
2Details on cost management strategies for R&D expenses.
3Any partnerships or collaborations that could enhance development efforts.
4Insights into market demand for their therapies.
5Management's outlook on future revenue growth.